IP
IMUC

Intellectus Partners’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Intellectus Partners’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,707
Closed -$9K – 822
2017
Q1 		$9K Hold
2,707
– – ﹤0.01% 553
2016
Q4 		$6K Buy
+2,707
New +$8.58K ﹤0.01% 580

Other funds holding IMUC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Intellectus Partners's IMUC Position: Q2 2017 in Review

Intellectus Partners sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2017, closing a stake of 2,707 shares — an estimated $9K sold.

Intellectus Partners first reported a position in IMUC in Q4 2016 and held it in 2 quarters. The position peaked at $9K in Q1 2017. 16 funds tracked by Wall St. Rank hold IMUC as of Q2 2017.

  • Intellectus Partners reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2017 after selling out during the quarter.
  • Intellectus Partners sold 2,707 ImmunoCellular Therapeutics, Ltd. shares in Q2 2017, an estimated $9K.
  • Intellectus Partners first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2016 and held it in 2 quarters.
  • Intellectus Partners's ImmunoCellular Therapeutics, Ltd. position peaked at $9K in Q1 2017.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2017.

Based on Intellectus Partners's 13F filing for Q2 2017, filed 15 Aug 2017.